Alam Kamran's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed Aug 20, 2021
- Accession no.
- 0001209191-21-052824
- Filed
- Aug 20, 2021
- Trade date
- Aug 18-20, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $557.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Alam KamranCIK 0001793412 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2021 | Common Stock | SSaleDisposed | −11,193 | $17.35 | −$194,198.55 | 319,928 | Direct | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −9,354 | $16.43 | −$153,686.22 | 310,574 | Direct | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −613 | $17.11 | −$10,488.43 | 309,961 | Direct | |
| Aug 20, 2021 | Common Stock | SSaleDisposed | −9,746 | $16.70 | −$162,758.2 | 300,215 | Direct | |
| Aug 20, 2021 | Common Stock | SSaleDisposed | −2,094 | $17.14 | −$35,891.16 | 298,121 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.